SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ...

Bank of America Securities analyst Alec Stranahan upgraded Erasca (ERAS – Research Report) to a Buy today and set a price target of $5.00. The ...

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

This important study leverages the power of Drosophila genetics and sparsely-labeled neurons to propose a new model for neuronal injury signaling. The authors present convincing evidence to support ...

Peptides, as versatile biological molecules, have garnered significant attention in scientific research due to their ...

Peptides, short chains of amino acids, have been extensively studied for their potential role in mitigating bone degradation.

USA News Group   News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before.